Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals

Molecular and Cellular Probes

Volumn 26, Issue 2, 2012, Pages 73-80

  Dauner, Joseph G ^a   Pan, Yuanji ^a   Hildesheim, Allan ^b   Kemp, Troy J ^a   Porras, Carolina ^c   Pinto, Ligia A ^a  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Proyecto Epidemiológico Guanacaste   (United States)

Author keywords

Antibody; Avidity; HPV vaccine

Indexed keywords

ANTIGEN; GUANIDINE; WART VIRUS VACCINE;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VIRUS LIKE AGENT; WART VIRUS;

ANTIBODIES, VIRAL; ANTIBODY AFFINITY; CAPSID PROTEINS; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GUANIDINE; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATISTICS, NONPARAMETRIC; VACCINATION; VACCINES, VIRUS-LIKE PARTICLE;

HUMAN PAPILLOMAVIRUS;

EID: 84859002102     PISSN: 08908508     EISSN: 10961194     Source Type: Journal    
DOI: 10.1016/j.mcp.2012.01.002     Document Type: Article

References (39)

1. Dziemian E., Zarnowska H., Kolodziej-Sobocinska M., Machnicka B. Determination of the relative avidity of the specific IgG antibodies in human toxocariasis. Parasite Immunol 2008, 30:187-190.
2. Motran C.C., Cerban F.M., Rivarola H.W., Vottero de Cima E. Characterization of autoantibodies generated in mice by immunization with the C-terminal region of Trypanosoma cruzi ribosomal P1 and P2 proteins. Clin Immunol 1999, 91:17-24.
3. Narita M., Matsuzono Y., Takekoshi Y., Yamada S., Itakura O., Kubota M., et al. Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G. Clin Diagn Lab Immunol 1998, 5:799-803.
4. Raviprakash K., Porter K.R., Kochel T.J., Ewing D., Simmons M., Phillips I., et al. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 2000, 81:1659-1667.
5. Yasodhara P., Ramalakshmi B.A., Sarma M.K. A new approach to differentiate recent vs chronic toxoplasma infection: avidity elisa in toxoplasma serology. Indian J Med Microbiol 2001, 19:145-148.
6. Anttila M., Eskola J., Ahman H., Kayhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 1998, 177:1614-1621.
7. Hedman K., Seppala I. Recent rubella virus infection indicated by a low avidity of specific IgG. J Clin Immunol 1988, 8:214-221.
8. Perciani C.T., Peixoto P.S., Dias W.O., Kubrusly F.S., Tanizaki M.M. Improved method to calculate the antibody avidity index. J Clin Lab Anal 2007, 21:201-206.
9. Polack F.P., Hoffman S.J., Crujeiras G., Griffin D.E. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med 2003, 9:1209-1213.
10. Romero-Steiner S., Holder P.F., Gomez de Leon P., Spear W., Hennessy T.W., Carlone G.M. Avidity determinations for Haemophilus influenzae Type b anti-polyribosylribitol phosphate antibodies. Clin Diagn Lab Immunol 2005, 12:1029-1035.
11. Rychert J., Amedee A.M. The antibody response to SIV in lactating rhesus macaques. J Acquir Immune Defic Syndr 2005, 38:135-141.
12. Ward K.N., Dhaliwal W., Ashworth K.L., Clutterbuck E.J., Teo C.G. Measurement of antibody avidity for hepatitis C virus distinguishes primary antibody responses from passively acquired antibody. J Med Virol 1994, 43:367-372.
13. Westerlund A., Ankelo M., Ilonen J., Knip M., Simell O., Hinkkanen A.E. Absence of avidity maturation of autoantibodies to the protein tyrosine phosphatase-like IA-2 molecule and glutamic acid decarboxylase (GAD65) during progression to type 1 diabetes. J Autoimmun 2005, 24:153-167.
14. Arias-Bouda L.M., Kuijper S., Van der Werf A., Nguyen L.N., Jansen H.M., Kolk A.H. Changes in avidity and level of immunoglobulin G antibodies to Mycobacterium tuberculosis in sera of patients undergoing treatment for pulmonary tuberculosis. Clin Diagn Lab Immunol 2003, 10:702-709.
15. Breukels M.A., Jol-van der Zijde E., van Tol M.J., Rijkers G.T. Concentration and avidity of anti-Haemophilus influenzae type b (Hib) antibodies in serum samples obtained from patients for whom Hib vaccination failed. Clin Infect Dis 2002, 34:191-197.
16. Harris S.L., Tsao H., Ashton L., Goldblatt D., Fernsten P. Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays. Clin Vaccine Immunol 2007, 14:397-403.
17. Romero-Steiner S., Musher D.M., Cetron M.S., Pais L.B., Groover J.E., Fiore A.E., et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999, 29:281-288.
18. McCloskey N., Turner M.W., Goldblatt T.D. Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA). J Immunol Methods 1997, 205:67-72.
19. Macdonald R.A., Hosking C.S., Jones C.L. The measurement of relative antibody affinity by ELISA using thiocyanate elution. J Immunol Methods 1988, 106:191-194.
20. de Souza V.A., Pannuti C.S., Sumita L.M. de Andrade Junior HF. Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines. J Med Virol 1997, 52:275-279.
21. Pullen G.R., Fitzgerald M.G., Hosking C.S. Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods 1986, 86:83-87.
22. Kirnbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992, 89:12180-12184.
23. Kirnbauer R., Taub J., Greenstone H., Roden R., Durst M., Gissmann L., et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993, 67:6929-6936.
24. Hildesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Bratti M.C., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. Jama 2007, 298:743-753.
25. Pinto L.A., Edwards J., Castle P.E., Harro C.D., Lowy D.R., Schiller J.T., et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 2003, 188:327-338.
26. Dessy F.J., Giannini S.L., Bougelet C.A., Kemp T.J., David M.P., Poncelet S.M., et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008, 4:425-434.
27. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.
28. Christensen N.D., Dillner J., Eklund C., Carter J.J., Wipf G.C., Reed C.A., et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996, 223:174-184.
29. Roden R.B., Armstrong A., Haderer P., Christensen N.D., Hubbert N.L., Lowy D.R., et al. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol 1997, 71:6247-6252.
30. Polanec J., Seppala I., Rousseau S., Hedman K. Evaluation of protein-denaturing immunoassays for avidity of immunoglobulin G to rubella virus. J Clin Lab Anal 1994, 8:16-21.
31. Vermont C.L., van Dijken H.H., van Limpt C.J., de Groot R., van Alphen L., van Den Dobbelsteen G.P. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine. Infect Immun 2002, 70:584-590.
32. Chargelegue D., Stanley C.M., O'Toole C.M., Colvin B.T., Steward M.W. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression. Clin Exp Immunol 1995, 99:175-181.
33. Ek T., Mellander L., Hahn-Zoric M., Abrahamsson J. Avidity of tetanus and Hib antibodies after childhood acute lymphoblastic leukaemia - implications for vaccination strategies. Acta Paediatr 2006, 95:701-706.
34. Schlesinger Y., Granoff D.M. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. Jama 1992, 267:1489-1494.
35. Denoel P.A., Goldblatt D., de Vleeschauwer I., Jacquet J.M., Pichichero M.E., Poolman J.T. Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines. Clin Vaccine Immunol 2007, 14:1362-1369.
36. Longworth E., Borrow R., Goldblatt D., Balmer P., Dawson M., Andrews N., et al. Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine 2002, 20:2592-2596.
37. Nair N., Gans H., Lew-Yasukawa L., Long-Wagar A.C., Arvin A., Griffin D.E. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis 2007, 196:1339-1345.
38. Poolman J., Kaufhold A., De Grave D., Goldblatt D. Clinical relevance of lower Hib response in DTPa-based combination vaccines. Vaccine 2001, 19:2280-2285.
39. Wuorimaa T., Dagan R., Vakevainen M., et al. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J Infect Dis 2001, 184:1211-1215.